Abstract
The kinase-targeted drug market is forecast to reach $58.6 billion in 2010.
D&MD's Kinases: Advanced Strategies for Drug Discovery market analysis report
comprehensively reviews protein kinases and assesses their importance as drug
targets. Approaches to kinase drug discovery are evolving. Small molecule
inhibitors now encompass rationally-designed single-target inhibitors and
multi-target inhibitors developed with the aid of new screening and profiling
assays. Innovative biopharmaceuticals are making inroads into the market. The
range of indications for kinase-targeted drugs is expanding.
During the last five years, eight anticancer kinase inhibitors received FDA
approval, including multi-kinase inhibitors, the first of which was approved
by the FDA in December 2005. The launched drugs are discussed in this report,
as are similar agents that are following in their track. At the same time,
recent discoveries of activating and resistance kinase mutations have been
driving the development of molecularly targeted anticancer therapies and we
review progress in this area. An on-line survey conducted specially for this
report shows that kinases (alongside GPCRs), are currently regarded as
commercially the most promising targets available to the drug industry. The
facts and analysis provided by this report help companies prepare themselves
to exploit these targets.
Chapter 1: E xecutive Summary
During the last five years, eight anticancer kinase inhibitors received FDA
approval, increasing recognition of kinases as an important class of drug
targets. In order to comprehensively assess the scientific, clinical, and
commercial progress and prospects in this field, the following surveys were
carried out exclusively for this report: a search of Pharmaprojects, the
leading database tracking pharmaceutical R&D worldwide; a survey of the last
six years of kinase-related patenting at the US PTO; and an on-line survey of
pharmaceutical industry and academic personnel. We forecast that the
kinase-targeted drug market will grow from $12.7 billion in 2005 to $58.6
billion in 2010. Cancer (mainly solid tumors) will remain the dominant
application throughout the forecast period.
Reversible protein phosphorylation, catalyzed by kinases, is a ubiquitous
mechanism for the control of signal transduction networks that regulate many
vital biological processes. Cancer and other proliferation-related disorders
are associated with stimulation of intra-cellular signaling, and since kinases
(most of the time) positively relay signaling events; their inhibition offers
a powerful way to block aberrant signal transduction cascades. The focus
throughout this report is on inhibitors of protein kinases, although, where
appropriate, protein kinase stimulators are also discussed, as are modulators
of lipid and sugar kinases. The search of the Pharmaprojects database
generated 803 drug profiles representing 243 unique companies, 184 unique
targets, and 68 unique indications/drug types. A subsequent search of the
Entrez Gene database for human genes with kinase activity led us to conclude
that (according to Pharmaprojects) 145 kinase-related genes are currently drug
targets, while 627 kinase-related genes remain unexplored as drug targets.
Examination of the Pharmaprojects dataset revealed that the kinase drug market
is at an early stage; overall 80% of drugs are still in preclinical
development. By far the largest indication for kinase-targeted drugs, almost
41% of the total, is cancer. Of the top five kinase drug targets, only one is
not primarily a cancer target. Other important indications for kinase-targeted
drugs include inflammation, arthritis, diabetes, and cardiovascular disease.
Of the top ten companies most active in this area, only Pfizer, Novartis,
AstraZeneca, and GlaxoSmithKline have launched products.
Currently, the emphasis is on small molecule approaches to kinase inhibition.
The majority of the respondents to our on-line survey felt that small molecule
inhibitors were preferable to monoclonal antibodies and that multi-target
kinase inhibitors were more likely to prove commercially successful than
single-target inhibitors. Now that many kinases have been sequenced and their
structures have been determined, more efficient approaches to small molecule
kinase inhibitor discovery are urgently needed. We discuss recent advances in
this area,
Buy this report and receive:
- Results from a survey of more than 800 kinase drugs and their targets to
give the reader an appreciation of the kinase drug landscape
- Current market size and forecasts to 2010 to assist the reader with
formulating business plans in the kinase drug area
- Analysis on the leading indications for kinase drugs and highlights in
areas of unmet needs to enable the reader to formulate a strategy for business
development
- Profiles of kinase-related patenting at the US PTO to help the reader
understand the area's evolving IP landscape, identify trends, improve
strategic approach and discover potential collaborative partners
- Comprehensive analysis of kinase drug targets through a gene family-based
approach to allow the reader to assess the drug development potential of
kinases belonging to particular families
Receive answers to crucial questions in this area such as:
- Which kinase targets are being pursued by drug developers?
- Which kinase targets have attracted the greatest amount of interest from
drug developers?
- What is the nature of commercial activity surrounding each major kinase
target?
- Which are the most important therapeutic indications for kinase drugs?
- What are the areas of unmet need that new kinase drugs could address?
- Which companies are the most prolific developers of kinase drugs and what
drugs are in their portfolios?
- Who are the most prolific assignees and which are the most frequently
cited kinase patents?
Recent approvals of several first-in-class kinase inhibitors have resulted in
increased recognition of kinases as an important class of drug targets. The
kinase market is still at an early stage, but many trends are already evident
and these are analyzed in this report. Already 145 kinase-related genes are
being targeted in kinase drug development, which nonetheless leaves a large
number (estimated 627) of potential targets unexplored. This report guides
readers in assessing or reassesing their strategies with respect to this
target class.
In order to comprehensively assess recent progress and prospects in the kinase
field, several surveys were carried out exclusively for this report, involving
searches of the Pharmaprojects database and the U.S. Patent and Trademark
Office database, and questioning of respondents from the pharmaceutical
industry. The information from the various surveys was utilized in the
analysis of individual kinase targets and families to which they belong.
| 
View Cart
